Deciphera pharmaceuticals, inc. (DCPH)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Dec'16
Assets
Current assets:
Cash and cash equivalents

229,652

120,320

173,712

57,237

82,228

293,764

320,875

346,527

179,873

196,754

-

57,461

Marketable securities

461,848

459,256

460,883

168,179

180,114

0

-

-

-

-

-

-

Accounts receivable

-

-

-

20,000

-

-

-

-

-

-

-

-

Unbilled receivable

-

-

-

5,000

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

11,979

13,832

7,700

6,010

4,103

7,273

4,734

2,221

1,241

1,428

-

791

Total current assets

703,479

593,408

642,295

256,426

266,445

301,037

325,609

348,748

181,114

198,182

-

58,252

Long-term investment—restricted

2,125

1,510

1,510

1,510

1,069

1,069

1,069

1,069

-

-

-

-

Property and equipment, net

6,693

6,333

5,274

1,595

1,504

13,453

19,238

18,264

952

838

-

514

Operating lease assets

20,630

21,158

522

476

670

0

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

104

Other assets

-

-

-

-

-

-

-

75

75

75

-

75

Total assets

732,927

622,409

649,601

260,007

269,688

315,559

345,916

368,156

182,141

199,095

-

58,945

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

11,337

19,575

14,770

13,900

10,937

8,308

6,051

6,938

5,556

4,395

-

1,413

Accrued expenses and other current liabilities

32,234

38,716

26,884

20,935

16,333

13,709

11,406

11,790

10,552

9,233

-

2,957

Operating lease liabilities

1,501

1,747

415

313

434

539

-

-

-

-

-

-

Notes payable to related party

-

-

187

187

187

187

187

187

187

187

-

187

Total current liabilities

45,072

60,038

42,256

35,335

27,891

22,743

17,644

18,915

16,295

13,815

-

4,557

Notes payable to related party, net of current portion

-

-

967

1,014

1,076

1,107

1,154

1,201

1,248

1,294

-

1,481

Operating lease liabilities, net of current portion

15,595

15,904

107

164

244

11,347

-

-

-

-

-

-

Lease liability, net of current portion

-

-

-

-

-

-

17,538

16,896

-

-

-

-

Other long-term liabilities

-

-

718

616

481

381

212

47

8

13

-

-

Total liabilities

60,667

75,942

44,048

37,129

29,692

35,578

36,548

37,059

17,551

15,122

-

6,038

Commitments and contingencies (Note 6)

-

-

-

-

-

-

0

0

0

-

-

0

Stockholders' equity:
Preferred stock, $0.01 par value per share; 5,000,000 shares authorized; no shares issued or outstanding

0

0

0

-

-

0

0

0

0

-

-

0

Convertible preferred shares (Series A, B-1, B-2, C), no par value; no shares and 3,632,711 authorized as of December 31, 2017 and 2016, respectively; no shares and 3,632,711 shares issued and outstanding as of December 31, 2017 and 2016

-

-

-

-

-

-

-

-

-

-

-

192,667

Common stock, $0.01 par value per share; 125,000,000 shares authorized; 55,681,027 shares and 51,617,639 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

557

516

510

382

382

377

377

376

326

326

0

-

Additional paid-in capital

1,231,726

1,033,819

1,025,745

586,888

582,700

575,327

572,415

569,710

381,563

379,516

-

5,825

Accumulated other comprehensive income (loss)

763

111

61

175

21

0

-

-

-

-

-

-

Accumulated deficit

-560,800

-487,979

-420,800

-364,567

-343,107

-295,723

-263,424

-238,989

-217,299

-195,869

-

-145,585

Total stockholders' equity

672,260

546,467

605,553

222,878

239,996

279,981

309,368

331,097

164,590

183,973

0

-139,760

Total members equity

-

-

-

-

-

-

-

-

-

-

-

-139,760

Total liabilities and stockholders' equity

732,927

622,409

649,601

260,007

269,688

315,559

345,916

368,156

182,141

199,095

-

58,945

Deciphera Pharmaceuticals, LLC [Member]
Cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

82,149

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

596

-

Total current assets

-

-

-

-

-

-

-

-

-

-

82,745

-

Property and equipment, net

-

-

-

-

-

-

-

-

-

-

731

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

4,316

-

Other assets

-

-

-

-

-

-

-

-

-

-

75

-

Assets

-

-

-

-

-

-

-

-

-

-

87,867

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

3,104

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

6,789

-

Notes payable to related party

-

-

-

-

-

-

-

-

-

-

187

-

Total current liabilities

-

-

-

-

-

-

-

-

-

-

10,080

-

Notes payable to related party, net of current portion

-

-

-

-

-

-

-

-

-

-

1,341

-

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

18

-

Total liabilities

-

-

-

-

-

-

-

-

-

-

11,439

-

Convertible preferred shares (Series A, B-1, B-2, C), no par value; 4,455,039 shares authorized at September 30, 2017 and 3,632,711 shares authorized as of December 31, 2016; 4,323,044 shares issued and outstanding as of September 30, 2017, 3,632,711 shares issued and outstanding as of December 31, 2016; aggregate liquidation preference of $246,388 as of September 30, 2017 and $194,088 as of December 31, 2016

-

-

-

-

-

-

-

-

-

-

244,538

-

Common shares, no par value; 5,217,929 shares authorized as of September 30, 2017 and 4,366,052 shares authorized as of December 31, 2016; no shares issued or outstanding as of September 30, 2017 or December 31, 2016

-

-

-

-

-

-

-

-

-

-

0

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

7,847

-

Accumulated deficit

-

-

-

-

-

-

-

-

-

-

-175,957

-

Total members' deficit

-

-

-

-

-

-

-

-

-

-

-168,110

-

Total liabilities, convertible preferred shares and members' deficit

-

-

-

-

-

-

-

-

-

-

87,867

-